US FDA Again Asked To Hold Off On Approval Of Ryoncil Pediatric Cell Therapy
Executive Summary
Attorney says new information Mesoblast submitted following ‘complete response’ letter does not include data from randomized controlled trial, which he says is needed to provide substantial evidence of efficacy in treatment of children with graft-versus-host disease.
You may also be interested in...
Mesoblast Plans Small Trial After Second CRL For GVHD Cell Therapy
Seeking approval for pediatric patients with acute graft-versus-host disease, Mesoblast gets a second US FDA complete response and now says it will seek to get needed data from a small trial in adults.
Mesoblast Plans Small Trial After Second CRL For GVHD Cell Therapy
Seeking approval for pediatric patients with acute graft-versus-host disease, Mesoblast gets a second US FDA complete response and now says it will seek to get needed data from a small trial in adults.
40+ Candidates Give US FDA Plenty Of Latitude While Growing 2023 Novel Approval Count From 2022
User fee goal dates in the second half of 2023 suggest cancer and breakthrough therapy approvals should recover from first-half dips and a resumption of inspections in China could revive COVID-delayed products.